SGN-40 (anti-huCD40 mAb)

DRUG3 trials

Sponsors

Seagen Inc.

Conditions

Leukemia, Lymphocytic, ChronicMultiple MyelomaNon-Hodgkin Lymphoma

Phase 1

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

CompletedNCT00079716

Seagen Inc.Multiple Myeloma

Start: 2004-03-31End: 2007-11-30Updated: 2014-12-18

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

CompletedNCT00103779

Seagen Inc.Non-Hodgkin Lymphoma

Start: 2004-12-31End: 2007-03-31Updated: 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

CompletedNCT00283101

Seagen Inc.Leukemia, Lymphocytic, Chronic

Start: 2005-07-31End: 2006-10-31Updated: 2014-12-18

Related Papers

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.

2010-02-04106 citations